home / stock / htsuf / htsuf news
Hisamitsu Pharmaceutical ([[HTSUF]]) company Noven Pharmaceuticals has submitted a New Drug Application to the U.S. FDA seeking approval to market its dextroamphetamine transdermal system ((ATS)) for the treatment of Attention Deficit Hyperactivity Disorder ((ADHD)).Noven’s ATS is...
Hisamitsu Pharmaceutical Co. ( OTCPK:HTSUF ) subsidiary Noven Pharmaceuticals announces the FDA nod for SECUADO (asenapine) transdermal patch for the treatment of adults with schizophrenia. More news on: Hisamitsu Pharmaceutical Co., Inc., Allergan plc, Merck & Co., Inc., Healthcare ...